Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · Real-Time Price · USD
33.10
-0.01 (-0.03%)
At close: Apr 28, 2026, 4:00 PM EDT
33.12
+0.02 (0.06%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Nanobiotix Employees
Nanobiotix had 103 employees as of June 30, 2025.
Employees
103
Change
n/a
Growth
n/a
Revenue / Employee
$371,536
Profits / Employee
-$273,137
Market Cap
1.61B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2025 | 103 | - | - | 103 | 0 |
| Dec 31, 2024 | 108 | 6 | 5.88% | 108 | 0 |
| Dec 31, 2023 | 102 | 0 | - | 102 | 0 |
| Dec 31, 2022 | 102 | 2 | 2.00% | 102 | 0 |
| Dec 31, 2021 | 100 | 10 | 11.11% | 100 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 711 |
| Intellia Therapeutics | 377 |
| Nurix Therapeutics | 317 |
| Nuvation Bio | 298 |
| Monte Rosa Therapeutics | 150 |
| AtaiBeckley | 99 |
| Rapport Therapeutics | 84 |
| MBX Biosciences | 63 |
NBTX News
- 8 days ago - Nanobiotix Announces Positive Preclinical Data For Nanoprimer In LNP-DNA Delivery - Nasdaq
- 8 days ago - Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology - GlobeNewsWire
- 21 days ago - Voting Rights and Shares Capital of the Company - GlobeNewsWire
- 27 days ago - Nanobiotix Earnings Call Transcript: H2 2025 - Transcripts
- 27 days ago - Nanobiotix FY25 Net Loss Narrows; Expects Cash Runway Through Early 2028; Stock Down - Nasdaq
- 4 weeks ago - NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results - GlobeNewsWire
- 4 weeks ago - NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026 - GlobeNewsWire
- 4 weeks ago - Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process - Benzinga